Related references
Note: Only part of the references are listed.High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: A prospective cohort study
Zhao-yan Liu et al.
LIVER INTERNATIONAL (2022)
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2022)
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
Daniel J. Rader et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna L. Attia et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits
Sarah Epperlein et al.
BIOMEDICINES (2021)
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
Metabolic Messengers: FGF21
Kyle H. Flippo et al.
NATURE METABOLISM (2021)
Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis
Jolana Wagner-Skacel et al.
NEUROPSYCHIATRIE (2021)
Circulating FGF21 Levels in Human Health and Metabolic Disease
Michaela Keuper et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2020)
Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy
Ling-ling Qian et al.
ACTA PHARMACOLOGICA SINICA (2020)
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Michael Ritchie et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
Mohammad Zarei et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase
Sangwon Byun et al.
NATURE COMMUNICATIONS (2020)
Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease
Bradley Tucker et al.
ATHEROSCLEROSIS (2020)
FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation
Helle Keinicke et al.
ENDOCRINE CONNECTIONS (2020)
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Genome-wide association study for circulating fibroblast growth factor 21 and 23
Gwo-Tsann Chuang et al.
SCIENTIFIC REPORTS (2020)
FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
Amos Baruch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States
Chiranjeevi Gadiparthi et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2020)
Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling
Qianqian Zheng et al.
THERANOSTICS (2020)
Epidemiology of non-alcoholic and alcoholic fatty liver diseases
Souveek Mitra et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application
Dicky Struik et al.
CURRENT OPINION IN LIPIDOLOGY (2019)
FGF19 subfamily members: FGF19 and FGF21
Katarzyna Dolegowska et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2019)
The roles of FGF21 in atherosclerosis pathogenesis
Farzane Shanebandpour Tabari et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2019)
Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure
Magdalene Ameka et al.
SCIENTIFIC REPORTS (2019)
Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016
Terrence Wong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Genetic Variants Flanking the FGF21 Gene Were Associated with Renal Function in Chinese Patients with Type 2 Diabetes
Weihui Yu et al.
JOURNAL OF DIABETES RESEARCH (2019)
FGF21 as Modulator of Metabolism in Health and Disease
Caterina Tezze et al.
FRONTIERS IN PHYSIOLOGY (2019)
NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
Alex Depaoli et al.
DIABETES (2019)
Association of the 3′UTR polymorphism (rs11665896) in the FGF21 gene with metabolic status and nutrient intake in children with obesity
Alan Joel Ruiz-Padilla et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2019)
Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
Ali Alqahtani et al.
MEDICINA-LITHUANIA (2019)
Going Back to the Biology of FGF21: New Insights
Jo E. Lewis et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease
Xin Su et al.
CLINICA CHIMICA ACTA (2019)
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
Edgar D. Charles et al.
OBESITY (2019)
Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer
Hongbo Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Fibroblast growth factor 21 in non-alcoholic fatty liver disease
Bradley Tucker et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Role of hepatokines in non-alcoholic fatty liver disease
Yini Ke et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2019)
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
Lucas D. BonDurant et al.
ANNUAL REVIEW OF NUTRITION, VOL 38 (2018)
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise
Vincent Wai-Sun Wong et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency
Jian Zhang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2018)
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Elliot B Tapper et al.
BMJ-British Medical Journal (2018)
A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure
Timothy M. Frayling et al.
CELL REPORTS (2018)
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Elliot B Tapper et al.
BMJ-British Medical Journal (2018)
FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest
Susanna Seberg et al.
MOLECULAR METABOLISM (2018)
Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet
Garima Singhal et al.
MOLECULAR METABOLISM (2018)
Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Max G. Griswold et al.
LANCET (2018)
Alcoholic liver disease
Helmut K. Seitz et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kook Hwan Kim et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
Ghada M. El Sagheer et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2018)
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
James J. Connolly et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2018)
FGF21 AND METABOLIC DISEASE IN 2016 A new frontier in FGF21 biology
Matthew J. Potthoff
NATURE REVIEWS ENDOCRINOLOGY (2017)
Fatty liver and FGF21 physiology
Eleftheria Maratos-Flier
EXPERIMENTAL CELL RESEARCH (2017)
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Ricardo J. Samms et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
Pegah Golabi et al.
MEDICINE (2017)
Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases
Liang Wu et al.
SCIENTIFIC REPORTS (2017)
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Lei He et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury
Bhavna N. Desai et al.
MOLECULAR METABOLISM (2017)
Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
Guangyu Wu et al.
SCIENTIFIC REPORTS (2017)
Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage
Yongde Luo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
Albert M. Kim et al.
DIABETES OBESITY & METABOLISM (2017)
FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans
Susanna Soberg et al.
CELL METABOLISM (2017)
Understanding the Physiology of FGF21
Ffolliott Martin Fisher et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
FGF21 Regulates Sweet and Alcohol Preference
Saswata Talukdar et al.
CELL METABOLISM (2016)
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar et al.
CELL METABOLISM (2016)
FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
Christian Schlein et al.
CELL METABOLISM (2016)
Macronutrient Intake-Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial
Yoriko Heianza et al.
DIABETES CARE (2016)
Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease
Fei Fei Shen et al.
Journal of Digestive Diseases (2016)
FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
Shenglong Zhu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury
Yanlong Liu et al.
SCIENTIFIC REPORTS (2016)
Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice
Fenni Rusli et al.
SCIENTIFIC REPORTS (2016)
Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
Nobuyuki Itoh et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Rohit Loomba et al.
GASTROENTEROLOGY (2015)
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
Ganesh Kolumam et al.
EBIOMEDICINE (2015)
FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway
Shenglong Zhu et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2014)
Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
Ffolliott M. Fisher et al.
GASTROENTEROLOGY (2014)
Fibroblast Growth Factor Signaling in Liver Carcinogenesis
Dalbir S. Sandhu et al.
HEPATOLOGY (2014)
Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009 An Analysis of 1066 Cases of a German HCC Registry
Arndt Weinmann et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2014)
The Single Nucleotide Polymorphism rs499765 Is Associated with Fibroblast Growth Factor 21 and Nonalcoholic Fatty Liver Disease in a Chinese Population with Normal Glucose Tolerance
Shan Jiang et al.
JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS (2014)
Hepatocellular carcinoma: epidemiology and risk factors
Michael C. Kew
JOURNAL OF HEPATOCELLULAR CARCINOMA (2014)
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress
Chaofeng Yang et al.
BMC GASTROENTEROLOGY (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
Global burden of alcoholic liver diseases
Juergen Rehm et al.
JOURNAL OF HEPATOLOGY (2013)
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Alexei Kharitonenkov et al.
PLOS ONE (2013)
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
Clarence Hale et al.
ENDOCRINOLOGY (2012)
Serum FGF21 and RBP4 levels in patients with chronic hepatitis C
Michal Kukla et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
Cobalt chloride decreases fibroblast growth factor-21 expression dependent on oxidative stress but not hypoxia-inducible factor in Caco-2 cells
Yanlong Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study
Hongmei Yan et al.
PLOS ONE (2011)
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Ffolliott M. Fisher et al.
DIABETES (2010)
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Jody Dushay et al.
GASTROENTEROLOGY (2010)
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway
Mary D. L. Chau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Heritability of Nonalcoholic Fatty Liver Disease
Jeffrey B. Schwimmer et al.
GASTROENTEROLOGY (2009)
Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver
Javier Garcia-Villafranca et al.
BIOCHIMIE (2008)
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
Xinmei Zhang et al.
DIABETES (2008)
Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
Asmaa Ibrahim Gomaa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor Isoforms determines metabolic activity of FGF19 and FGF21
Hiroshi Kurosu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis
Xinqiang Huang et al.
MOLECULAR CARCINOGENESIS (2006)
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis
CS Lieber
ALCOHOL (2004)
The role of AMP-activated protein kinase in the action of ethanol in the liver
M You et al.
GASTROENTEROLOGY (2004)
Lower risk for alcohol-induced cirrhosis in wine drinkers
U Becker et al.
HEPATOLOGY (2002)
Share Paper
